Aclaris Phase 2b zunsemetinib fails endpoints; ATI-450 program discontinued

Aclaris Therapeutics, Inc.

Study of oral MK2 inhibitor zunsemetinib (20mg or 50mg BID) in 251 RA patients did not meet primary endpoint ACR20 at week 12.
No differentiation from placebo on secondary endpoints (ACR50, ACR70, DAS28-CRP); no meaningful safety findings.
Aclaris discontinues ATI-450 development; halts enrollment in Phase 2a psoriatic arthritis trial.
Phase 2b results for ATI-1777 (topical JAK1/3) in atopic dermatitis expected year-end 2023; Phase 2 for ATI-2138 planned early 2024.
Cash, cash equivalents and marketable securities of $187.0M as of Sep 30, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.